An automated platform for the large-scale production of miniaturized neuromuscul...
An automated platform for the large-scale production of miniaturized neuromuscular organoids
Organoids have been developed as advanced 3D cell culture systems that resemble aspects of the in vivo tissues and provide an alternative to study the mechanisms of human disease and identify novel treatments. The last years have...
Organoids have been developed as advanced 3D cell culture systems that resemble aspects of the in vivo tissues and provide an alternative to study the mechanisms of human disease and identify novel treatments. The last years have witnessed tremendous developments in the field of stem cell and organoid research, but the full potential of these systems remains to be exploited. Two major challenges facing the organoid field are reproducibility and scalability. The manual production of organoids is a labor-intensive and expensive process. The development of cost-effective, fast, and reliable methods is a prerequisite for transferring organoid technologies to the industry for high-throughput approaches. We have recently established a novel complex human neuromuscular organoid (NMO) model from human pluripotent stem cell-derived neuromesodermal progenitors. NMOs self-organize into spinal cord neurons and skeletal muscle compartments that contract by forming functional neuromuscular junctions. The ERC consolidator grant GPSorganoids focuses on the generation of position-specific (GPS) NMOs representing distinct spinal cord segments and the use of such NMOs models to study the selective vulnerability of specific spinal cord neurons to neuromuscular diseases like amyotrophic lateral sclerosis and spinal muscular atrophy. The PoC grant goes beyond the scope of our ERC consolidator grant and focuses on the commercialization of the NMO model through the establishment of an automated, reliable, and high throughput production line that could apply to industry settings. Our ultimate goal is to establish NMOs as a leading model in the market for high throughput drug screening approaches and accelerate the development of novel therapies for neuromuscular disorders.ver más
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
01-11-2024:
ENESA
En las últimas 48 horas el Organismo ENESA ha otorgado 6 concesiones
01-11-2024:
FEGA
En las últimas 48 horas el Organismo FEGA ha otorgado 1667 concesiones
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.